| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 1,588.6 | 1,460.3 |
| Gross profit | 710.8 | 645.9 |
| Profit before tax | 288.0 | 253.1 |
| Net income | 213.7 | 191.9 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +11.4% |
|---|---|
| Revenue, year on year | +8.8% |
| Gross margin | 44.7% |
| Operating margin | 18.5% |
10-Q filed with the SEC, NYSE: STE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Steris plc: key numbers
- Share price
- $261.91Close, Nov 16
- Market cap
- $25.4B
- Shares outstanding
- 97.11MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Steris plc
All →Steris Sr. Vice Pres., CFO Karen L. Burton Sells $1.5M of Stock
Karen L. Burton, Sr. Vice Pres., CFO, sold 5,880 shares of Steris plc at $255.62 a share, worth $1.5M in total on Nov 11, 2026. Shares held after the trade: 12,956 (-31.2%).
- Value
- $1.5M
- Shares
- 5,880
- Price
- $255.62
- Role
- Sr. Vice Pres., CFO
- Holding change
- -31.2%
- Trade date
- Nov 11, 2026
Steris Insider Mohsen Sohi Sells $1.24M of Stock
Mohsen Sohi sold 4,893 shares of Steris plc at $252.87 to $253.90 a share (average $253.22) in 2 transactions, worth $1.24M in total on Nov 10, 2026. Shares held after the trade: 24,305 (-6.4%).
- Value
- $1.24M
- Shares
- 4,893
- Average price
- $253.22
- Holding change
- -6.4%
- Trade date
- Nov 10, 2026
Steris $1.5B Debt Financing with J.P. Morgan Securities LLC
STERIS plc's subsidiary, STERIS Irish FinCo Unlimited Company, priced an offering of $1.5 billion in senior notes, consisting of $750 million due 2033 at 5.650% and $750 million due 2036 at 5.875%. The proceeds will be used to fund the pending acquisition of Xodus Medical, Inc., transaction expenses, and general corporate purposes.
- Value
- $1.5B
- Counterparty
- J.P. Morgan Securities LLC
Steris $1.6B Debt Financing with JPMorgan Chase Bank, N.A.
STERIS plc entered into a new $1.6 billion revolving credit agreement with JPMorgan Chase Bank and other lenders, replacing its existing 2024 facility. The new facility matures on November 4, 2031, and includes an accordion feature allowing for an incremental increase of up to $800 million. The proceeds will be used for general corporate purposes, including swingline borrowings and letters of credit.
- Value
- $1.6B
- Counterparty
- JPMorgan Chase Bank, N.A.
- Term
- 5 years
Steris Financial Results
STERIS reported fiscal 2027 second quarter revenue of $1.6 billion, a 9% increase driven by strong performance in the Life Sciences segment. Adjusted EPS rose to $2.94, benefiting from approximately $20 million in tariff refunds. The company raised its full-year outlook based on solid underlying demand and segment performance.
- Term
- Q2 2027
“Life Sciences delivered particularly strong performance in the quarter, giving us confidence to raise our expectations for the segment for the full year. Our updated outlook reflects stable underlying performance, plus the benefit of tariff refunds received year-to-date. Fiscal 2027 is shaping up to be another record year for STERIS, supported by solid underlying demand and excellent execution from our commercial teams.”
Dan Carestio, President and CEO of STERIS
Steris Signs $2.1B M&A Deal with Xodus Medical, Inc.
STERIS plc, through its subsidiary, has entered into a definitive agreement to acquire Xodus Medical, Inc., a specialty surgical products business, for $2.1 billion in cash. The deal includes potential additional earnout consideration of up to $150 million based on 2028 performance targets and is expected to close by December 31, 2026. STERIS has secured a $2.0 billion bridge financing commitment from JPMorgan and Goldman Sachs to support the acquisition.
- Value
- $2.1B
- Counterparty
- Xodus Medical, Inc.